Menotropins

Limits on what this shows

• Null/negative findings: None identified specific to hMG; comparative literature on gonadotropin type and granulosa mitochondrial function is sparse.
• At-risk subgroups: None identified; the signal, such as it is, runs reassuring rather than risk-conferring.
• Counter-evidence: None located; this was the only drug-specific comparative mitochondrial study found despite multiple search attempts across PubMed listing pages, Crossref, and Semantic Scholar.

Regulatory status

Not addressed on the label; no mitochondrial-toxicity signal listed.

Population evidence

Saito N, Yamashita Y, Ono Y, et al., "Difference in mitochondrial gene expression in granulosa cells between recombinant FSH and hMG cycles under in vitro fertilization and transfer" (2013). Accessed via Crossref bibliographic/abstract metadata; the PubMed and journal pages were blocked by bot-verification during this review, so exact sample size and confidence intervals could not be independently confirmed beyond the abstract text. [Tier B - mechanistic/comparative, this drug directly in the design] Reported: "mitochondria mRNA expression was higher in the hMG cycle than in the recFSH cycle" and "the high-quality embryo rate in the hMG cycle was higher than in the recFSH cycle."

Mechanism

LH activity present in hMG (absent from pure recombinant FSH) supports theca-cell androgen substrate for granulosa aromatization and is proposed to up-regulate granulosa-cell mitochondrial transcription relative to FSH-only stimulation; not confirmed at the protein or functional (ATP) level in this study.

Counter-evidence held on record

Do not read this as menotropins "boosting" mitochondrial health for marketing purposes. It is a single, small, mRNA-level comparative study in granulosa cells, not a systemic patient-level mitochondrial-burden finding, and licenses no supplement claim in either direction.

Limits on what this shows

• Null/negative findings: Study (a) found no significant between-protocol difference in the oxidative markers themselves (SOD p=0.289, MDA p=0.561) - counter-evidence against attributing the change to a specific protocol/drug choice rather than to stimulation generally.
• At-risk subgroups: None specific to menotropins identified.
• Counter-evidence: No menotropins-specific serum oxidative-stress study was located despite searches across PubMed search-listing pages, Crossref, and Semantic Scholar this session. Europe PMC and NCBI Bookshelf/PMC full text were blocked by bot-verification and rate-limiting throughout this review and could not be checked; a revision should retry "menotropins" or "hMG" plus oxidative-stress terms against those channels specifically.

Regulatory status

Not addressed on the label.

Population evidence

(a) GnRH agonist/antagonist protocol comparison, n=82 (58 antagonist, 24 agonist), recombinant FSH 150-300 IU/day: serum SOD fell from ~17.5 to ~14.3 U/L (p<0.001 both protocols) and MDA rose from ~1.39 to ~1.75 µmol/L (p<0.001-0.003), no significant difference between protocols after stimulation. [Tier C for menotropins - drug confirmed absent from cohort] (b) Endometriosis-vs-control ICSI cohort, n=113 (60 controls, 53 endometriosis), recombinant FSH 150-300 IU/day (Gonal-F/Puregon), eight serum markers (FOX1, MDA, AOPP, 8OHdG, GSH, vitamin E, SOD, TAC) across four cycle timepoints. [Tier C for menotropins - drug again confirmed absent]

Mechanism

Ovarian stimulation drives rapid granulosa-cell proliferation and a several-fold estradiol rise, a physiologic burst plausibly increasing systemic reactive-oxygen generation regardless of which FSH source drives it; the mechanism does not depend on the specific gonadotropin molecule.

Counter-evidence held on record

This is class-level extrapolation, not a menotropins-specific finding. It should never be presented to a consumer as "Menopur causes oxidative stress" - the supporting data comes from a different gonadotropin product.

Limits on what this shows

• Null/negative findings: None identified.
• At-risk subgroups: None identified; magnitude and clinical significance in gonadotropin-stimulated women is unestablished.
• Counter-evidence: None identified, but the absence of any human or gonadotropin-specific study is itself a major limitation, disclosed here rather than glossed over.

Regulatory status

Not addressed on the label; no drug/copper interaction studies exist (label states no human drug/drug interaction studies were conducted at all).

Population evidence

Sunderman FW Jr, Nomoto S, Gillies CG, Goldblatt PJ, "Effect of estrogen administration upon ceruloplasmin and copper concentrations in rat serum" (1971). [Tier B, animal, estrogen administered directly, gonadotropin not administered] A direct PubMed term search for "menotropins AND copper" returned zero results; no human or hMG-specific copper study was located.

Mechanism

Estrogen induces hepatic synthesis of ceruloplasmin, the major copper-transport protein, secondarily raising total serum copper. Menotropins does not act on copper handling directly; it drives supraphysiologic ovarian estradiol production, one step removed from the drug molecule itself.

Counter-evidence held on record

This is an indirect, animal-derived, upward-direction (excess/retention, not deficiency) signal per Hard Rule 5. It supports neither copper supplementation nor copper restriction in menotropins-treated patients; the practical takeaway is "insufficient human data," not "confirmed excess."

Limits on what this shows

• Why no grade: A direct PubMed term search for "menotropins AND iron" returned four results, all concerning use of hMG/hCG to induce puberty or spermatogenesis in beta-thalassemia patients (a population with transfusion iron overload, using hMG to treat the hypogonadism thalassemia itself causes) - none measured an effect of menotropins on iron status. No Tier B mechanistic or Tier C class-level study linking menotropins, hMG, or gonadotropins generally to iron depletion or excess was located, and no circulating consumer claim attributing an iron effect to menotropins/Menopur was identified. Both dual conditions for ungraded are met.

Access note

Europe PMC and NCBI Bookshelf/PMC full text were blocked by bot-verification and rate-limiting throughout this review and could not be searched directly for iron. A later revision should retry "menotropins iron," "hMG ferritin," and "gonadotropin iron metabolism" against those channels specifically before this gap is considered fully closed.

Limits on what this shows

• Null/negative findings: None identified; this is an emerging, single-cohort association.
• At-risk subgroups: Poor ovarian responders (association, not menotropins-specific causation).
• Counter-evidence: None identified; the principal limitation is drug-identity ambiguity in the primary sources, disclosed above rather than assumed favorable.

Regulatory status

Not addressed on the label.

Population evidence

(a) Human IVF cohort, n=47 cycles (22 poor-response, follicle-to-oocyte index [FOI]<0.5; 25 adequate-response, FOI≥0.5), gonadotropin dosed 75-300 IU/day, brand/type unspecified. Poor responders showed relative enrichment of Prevotella copri, Bacteroides vulgatus, Escherichia coli, and Bacteroides stercoris; adequate responders showed relative enrichment of Bifidobacterium longum, Faecalibacterium prausnitzii, Ruminococcus gnavus, and Bifidobacterium pseudocatenulatum. Microbiome alteration correlated with serum estradiol, FSH, oocyte count, and pregnancy rate after age/BMI adjustment. [Tier C for menotropins - drug not confirmed in cohort] (b) A mouse model of repeated ovarian hyperstimulation and gut microbiota composition change exists in the literature (title-confirmed) but its full text could not be opened this session (bot-verification block), and the inducing hormone (PMSG/eCG vs. hCG) could not be confirmed - listed in Sources as an inaccessible lead, not used as supporting evidence.

Mechanism

Proposed link runs through estradiol-driven changes in gut epithelial permeability and bile-acid/estrogen-microbiome crosstalk, established generally for estrogen and the gut microbiome, applicable to any gonadotropin-driven stimulation and not specific to the menotropins molecule.

Counter-evidence held on record

This is a correlative, single-cohort finding with unconfirmed drug identity, not an established menotropins effect on the microbiome. It should not be presented as a menotropins-specific gut-health warning.

Limits on what this shows

• Null/negative findings: None identified for non-OHSS cycles, where hematocrit is not expected to change from the drug itself.
• At-risk subgroups: OHSS patients; those with pre-existing thrombosis risk factors per label.
• Counter-evidence: None identified.

Regulatory status

Label lists "hematocrit" among required daily acute-phase labs and documents "hemoconcentration" among OHSS clinical findings, alongside thromboembolic reactions (venous thrombophlebitis, pulmonary embolism, stroke, arterial occlusion). [Tier A, source 1]

Population evidence

Qualitative label finding tied to the same 7.2% OHSS incidence (source 1). A further lead, "Hematocrit as a simple method to predict and manage ovarian hyperstimulation syndrome," could not be opened this session (access error) and is listed in Sources as inaccessible, not used as supporting evidence.

Mechanism

Capillary leak moves plasma out of the vascular space while red-cell mass is unchanged, mechanically concentrating the blood - the same fluid-shift process producing the sodium and potassium findings above (see Overlap map), and the physiological basis for the label's thromboembolism warnings, not a hemoglobin-synthesis or oxygen-carrying-capacity effect.

Counter-evidence held on record

Per Hard Rule 2, this is the syndrome's own pathophysiology tracked via a hematologic marker, not a nutrient-deficiency finding: it is neither anemia nor an oxygen-delivery deficiency, and it supplies no basis whatsoever for iron or any hematinic supplementation. The correct response is fluid and electrolyte management, never a supplement.